Does rivaroxaban have a role in treating patients with PAD?
- PMID: 31241606
- DOI: 10.1097/01.JAA.0000558364.85986.ad
Does rivaroxaban have a role in treating patients with PAD?
Abstract
Peripheral arterial disease can cause devastating health outcomes, and few therapies are available to treat this condition. Results of a secondary analysis of the COMPASS trial suggest benefit with the use of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily. This treatment regimen could change the standard pharmacotherapeutic management practice for many patients with peripheral arterial disease.
Comment on
-
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. doi: 10.1016/j.jacc.2018.03.008. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540326 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
